These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

271 related articles for article (PubMed ID: 26244757)

  • 1. Fischer 344 Rat: A Preclinical Model for Epithelial Ovarian Cancer Folate-Targeted Therapy.
    Azaïs H; Queniat G; Bonner C; Kerdraon O; Tardivel M; Jetpisbayeva G; Frochot C; Betrouni N; Collinet P; Mordon S
    Int J Gynecol Cancer; 2015 Sep; 25(7):1194-200. PubMed ID: 26244757
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Assessment of the specificity of a new folate-targeted photosensitizer for peritoneal metastasis of epithelial ovarian cancer to enable intraperitoneal photodynamic therapy. A preclinical study.
    Azaïs H; Schmitt C; Tardivel M; Kerdraon O; Stallivieri A; Frochot C; Betrouni N; Collinet P; Mordon S
    Photodiagnosis Photodyn Ther; 2016 Mar; 13():130-138. PubMed ID: 26200606
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Specific folic-acid targeted photosensitizer. The first step toward intraperitoneal photodynamic therapy for epithelial ovarian cancer].
    Azaïs H; Frochot C; Grabarz A; Khodja Bach S; Colombeau L; Delhem N; Mordon S; Collinet P
    Gynecol Obstet Fertil Senol; 2017 Apr; 45(4):190-196. PubMed ID: 28359805
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [FRα: a target for prophylactic photodynamic therapy of ovarian peritoneal metastasis?].
    Azaïs H; Moussaron A; Khodja Bach S; Bassil A; Betrouni N; Frochot C; Collinet P; Mordon S
    Bull Cancer; 2014 Dec; 101(12):1109-13. PubMed ID: 25532689
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dual Targeting of Epithelial Ovarian Cancer Via Folate Receptor α and the Proton-Coupled Folate Transporter with 6-Substituted Pyrrolo[2,3-
    Hou Z; Gattoc L; O'Connor C; Yang S; Wallace-Povirk A; George C; Orr S; Polin L; White K; Kushner J; Morris RT; Gangjee A; Matherly LH
    Mol Cancer Ther; 2017 May; 16(5):819-830. PubMed ID: 28138029
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Folate receptor alpha antagonists in preclinical and early stage clinical development for the treatment of epithelial ovarian cancer.
    Bergamini A; Ferrero S; Leone Roberti Maggiore U; Scala C; Pella F; Vellone VG; Petrone M; Rabaiotti E; Cioffi R; Candiani M; Mangili G
    Expert Opin Investig Drugs; 2016 Dec; 25(12):1405-1412. PubMed ID: 27797594
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Folate-appended cyclodextrin carrier targets ovarian cancer cells expressing the proton-coupled folate transporter.
    Saito S; Koya Y; Kajiyama H; Yamashita M; Kikkawa F; Nawa A
    Cancer Sci; 2020 May; 111(5):1794-1804. PubMed ID: 32154964
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Intraperitoneal photodynamic therapy for peritoneal metastasis of epithelial ovarian cancer. Limits and future prospects].
    Azaïs H; Mordon S; Collinet P
    Gynecol Obstet Fertil Senol; 2017 Apr; 45(4):249-256. PubMed ID: 28373041
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Characterization of folate receptor alpha (FRα) expression in archival tumor and biopsy samples from relapsed epithelial ovarian cancer patients: A phase I expansion study of the FRα-targeting antibody-drug conjugate mirvetuximab soravtansine.
    Martin LP; Konner JA; Moore KN; Seward SM; Matulonis UA; Perez RP; Su Y; Berkenblit A; Ruiz-Soto R; Birrer MJ
    Gynecol Oncol; 2017 Nov; 147(2):402-407. PubMed ID: 28843653
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mirvetuximab Soravtansine (IMGN853), a Folate Receptor Alpha-Targeting Antibody-Drug Conjugate, Potentiates the Activity of Standard of Care Therapeutics in Ovarian Cancer Models.
    Ponte JF; Ab O; Lanieri L; Lee J; Coccia J; Bartle LM; Themeles M; Zhou Y; Pinkas J; Ruiz-Soto R
    Neoplasia; 2016 Dec; 18(12):775-784. PubMed ID: 27889646
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Improved Intraoperative Detection of Ovarian Cancer by Folate Receptor Alpha Targeted Dual-Modality Imaging.
    Hekman MCH; Boerman OC; Bos DL; Massuger LFAG; Weil S; Grasso L; Rybinski KA; Oosterwijk E; Mulders PFA; Rijpkema M
    Mol Pharm; 2017 Oct; 14(10):3457-3463. PubMed ID: 28826214
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Gene delivery with active targeting to ovarian cancer cells mediated by folate receptor alpha.
    He Z; Yu Y; Zhang Y; Yan Y; Zheng Y; He J; Xie Y; He G; Wei Y; Song X
    J Biomed Nanotechnol; 2013 May; 9(5):833-44. PubMed ID: 23802413
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Rigorous optimization and validation of potent RNA CAR T cell therapy for the treatment of common epithelial cancers expressing folate receptor.
    Schutsky K; Song DG; Lynn R; Smith JB; Poussin M; Figini M; Zhao Y; Powell DJ
    Oncotarget; 2015 Oct; 6(30):28911-28. PubMed ID: 26359629
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The Novel IκB Kinase β Inhibitor, IMD-0560, Has Potent Therapeutic Efficacy in Ovarian Cancer Xenograft Model Mice.
    Sawada I; Hashimoto K; Sawada K; Kinose Y; Nakamura K; Toda A; Nakatsuka E; Yoshimura A; Mabuchi S; Fujikawa T; Itai A; Kimura T
    Int J Gynecol Cancer; 2016 May; 26(4):610-8. PubMed ID: 26905334
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Targeted Photodynamic Therapy using a Vectorized Photosensitizer coupled to Folic Acid Analog induces Ovarian Tumor Cell Death and inhibits IL-6-mediated Inflammation.
    Boidin L; Moinard M; Moussaron A; Merlier M; Moralès O; Grolez GP; Baydoun M; Mohd-Gazzali A; Tazizi MHDM; Allah HHA; Kerbage Y; Arnoux P; Acherar S; Frochot C; Delhem N
    J Control Release; 2024 Jul; 371():351-370. PubMed ID: 38789088
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Abortifacient metapristone (RU486 derivative) interrupts CXCL12/CXCR4 axis for ovarian metastatic chemoprevention.
    Zheng N; Chen J; Li T; Liu W; Liu J; Chen H; Wang J; Jia L
    Mol Carcinog; 2017 Aug; 56(8):1896-1908. PubMed ID: 28277622
    [TBL] [Abstract][Full Text] [Related]  

  • 17. BCAT1 expression associates with ovarian cancer progression: possible implications in altered disease metabolism.
    Wang ZQ; Faddaoui A; Bachvarova M; Plante M; Gregoire J; Renaud MC; Sebastianelli A; Guillemette C; Gobeil S; Macdonald E; Vanderhyden B; Bachvarov D
    Oncotarget; 2015 Oct; 6(31):31522-43. PubMed ID: 26372729
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Folate receptor alpha (FRA) expression remains unchanged in epithelial ovarian and endometrial cancer after chemotherapy.
    Despierre E; Lambrechts S; Leunen K; Berteloot P; Neven P; Amant F; O'Shannessy DJ; Somers EB; Vergote I
    Gynecol Oncol; 2013 Jul; 130(1):192-9. PubMed ID: 23558051
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The folate receptor as a rational therapeutic target for personalized cancer treatment.
    Assaraf YG; Leamon CP; Reddy JA
    Drug Resist Updat; 2014; 17(4-6):89-95. PubMed ID: 25457975
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Immunotherapy targeting folate receptor induces cell death associated with autophagy in ovarian cancer.
    Wen Y; Graybill WS; Previs RA; Hu W; Ivan C; Mangala LS; Zand B; Nick AM; Jennings NB; Dalton HJ; Sehgal V; Ram P; Lee JS; Vivas-Mejia PE; Coleman RL; Sood AK
    Clin Cancer Res; 2015 Jan; 21(2):448-59. PubMed ID: 25416196
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.